
The FRESCO-2 trial evaluated the efficacy of fruquintinib (F), a novel selective oral VEGFR inhibitor, in heavily pre-treated patients with refractory metastatic colorectal cancer (mCRC). The trial compared F plus best supportive care (BSC) with placebo (P) plus BSC. The trial showed that F significantly improved overall survival (OS) and progression-free survival (PFS) compared to placebo (P). The median OS was 7.4 months for F and 4.8 months for P, and the median PFS was 3.7 months for F and 1.8 months for P. Fruquintinib was well-tolerated, with a safety profile consistent with previous findings. These results suggest that fruquintinib could be a valuable new treatment option for patients with refractory mCRC.
Like
Save
Share